Elmind Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Elmind Capital’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.01M	Hold	112,000	–	–	0.51%	28
2026 Q1	$1.56M	Hold	112,000	–	–	0.44%	30
2025 Q4	$1.35M	Buy	+112,000	New	+$1.52M	0.4%	31

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Elmind Capital's AMLX Position: Q2 2026 in Review

Elmind Capital held its Amylyx Pharmaceuticals (AMLX) position steady in Q2 2026 at 112,000 shares worth $2.01M. The position accounts for 0.51% of the portfolio, ranked #28.

Elmind Capital first reported a position in AMLX in Q4 2025 and has held it in 3 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Elmind Capital held 112,000 shares of Amylyx Pharmaceuticals worth $2.01M as of Q2 2026.
Elmind Capital left its Amylyx Pharmaceuticals share count unchanged in Q2 2026.
Amylyx Pharmaceuticals made up 0.51% of Elmind Capital's portfolio in Q2 2026, its #28 holding.
Elmind Capital first reported a position in Amylyx Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Elmind Capital's 13F filing for Q2 2026, filed 14 Aug 2026.